Edwards Sees ‘Tough Time’ Ahead For TAVR Patients
The COVID-19 pandemic is severely hindering patient access to transcatheter aortic valve replacement procedures. Edwards Lifesciences, the market leader, is hopeful that TAVR volumes will recover by the end of 2020, but that will be too late for many patients.
You may also be interested in...
The company recorded $925m in revenue in the second quarter of 2020, exceeding the top end of its previous guidance, and expects to return to growth by the end of the year.
Cardiology device firms relied primarily on in-house lobbyists but also recruited external groups to sway lawmakers to adopt favorable positions on reimbursement, COVID-19, international trade and other issues from January-March 2020, says this Medtech Insight analysis.
Edwards Lifesciences received the CE mark for its PASCAL transcatheter system for treating triscupid valve regurgitation, competing against Abbott’s newly CE-marked TriClip.